A deep dive into Abbott India Limited (ABBOTINDIA) — examining the financials, valuation picture, and who owns the stock.
Abbott India Revenue Trend
Top-line growth continued for Abbott India Limited, with FY2025 revenue reaching ₹6,409 Cr — a 5.1% increase over FY2024.
Abbott India Limited has compounded revenue at 10.8% over 10 years — good, consistent top-line expansion from ₹2,289 Cr to ₹6,409 Cr.
In terms of scale, Abbott India Limited's ₹6,409 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
The consistency stands out: 10 consecutive years of growth in top-line revenue.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹6,409 Cr | +5.1% |
| FY2024 | ₹6,097 Cr | +10.8% |
| FY2023 | ₹5,503 Cr | +10.1% |
| FY2022 | ₹4,996 Cr | +13.8% |
| FY2021 | ₹4,391 Cr | — |
View Abbott India Limited's full 10-year revenue trend with CAGR analysis →
Abbott India Profitability
The bottom line looked healthy: Abbott India Limited posted net profit of ₹1,414 Cr in FY2025, 17.8% above FY2024.
Net margin widened to 22.1% in FY2025 — an improvement from the 19.7% recorded in FY2024.
The diluted EPS figure moved up to ₹665.62 in FY2025, against ₹565.28 posted in FY2024.
Is Abbott India Undervalued
Using the P/E Ratio methodology, the calculated intrinsic value comes to ₹33,660.
Abbott India Limited shares are currently trading at ₹26,290.00.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹33,660 | 28.0% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Abbott India Limited with detailed assumptions →
Abbott India Shareholding Pattern
Promoters haven't moved — their 75.0% holding has been unchanged for 3 quarters.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Dec 2018 | 75.0% | 2.1% | 7.0% | 15.9% |
| Sep 2018 | 75.0% | 2.1% | 6.7% | 16.1% |
| Jun 2018 | 75.0% | 2.9% | 6.4% | 15.7% |
Track quarterly shareholding changes for Abbott India Limited →
Abbott India Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹59.17B (up 13.9% YoY from ₹51.93B).
Top categories: Other Assets (48.5%), Cash & ST Investments (27.5%), Inventories (14.9%).
Of the ₹59.17B in liabilities and equity, 71.5% is shareholder equity, 3.3% is interest-bearing debt, and 25.1% is operating liabilities. Over the year, debt is up 136.3% and equity is up 14.4%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 16.28B |
| Receivables | 3.80B |
| Inventories | 8.82B |
| Property, Plant & Equipment | 1.52B |
| Intangibles & Goodwill | 64.60M |
| Other Assets | 28.69B |
| Category | Value |
|---|---|
| Equity | 42.33B |
| Short-term Debt | 389.20M |
| Long-term Debt | 1.58B |
| Trade Payables | 10.58B |
| Other Liabilities | 4.30B |
What Stands Out About Abbott India
In summary, Abbott India Limited (ABBOTINDIA) presents the following picture for fundamental analysts.
Revenue of ₹6,409 Cr in FY2025, up 5.1% year-over-year.
Long-term revenue has been compounding at 10.8% annually over 10 years.
The company is profitable, with a net margin of 22.1% and net income of ₹1,414 Cr.
The P/E Ratio model implies 28.0% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Abbott India Limited.